AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Double strike against cancer

 cancer, drugs  Comments Off on Double strike against cancer
Jun 172013
 
Double strike against cancer
13.06.2013 – German researchers have found a way to circumvent chemotherapy resistance in cancer cells.

A new therapeutic approach can take advantage of cancer cells’ need to repair double-strand breaks in DNA, in order to overcome the tumour’s resistance to chemotherapy (Science Transl. Medicine). According to the research group headed by Hans Christian from University Cologne, mutations in the ATM gene protect cancer cells from cell death during chemotherapy. ATM  is instrumental in initiating DNA repair and inducing cell death when repair is not possible in curse of the so-called DNA damage response (DDR).  http://www.eurobiotechnews.eu/news/news/2013-02/double-strike-against-cancer.html

Share

ThromboGenics’ Jetrea receives NICE approval for eye condition treatment

 drugs  Comments Off on ThromboGenics’ Jetrea receives NICE approval for eye condition treatment
Jun 172013
 

http://drugdelivery.pharmaceutical-business-review.com/news/thrombogenics-jetrea-receives-nice-approval-for-eye-condition-treatment-130613

ThromboGenics’ Jetrea receives NICE approval for eye condition treatment 
Biopharmaceutical company ThromboGenics’ Jetrea has received approval from UK’s National Institute for Health and Care Excellence (NICE) in the treatment of some adults with vitreomacular traction (VMT), a rare eye condition…

Ocriplasmin (trade name Jetrea) is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from theretina.[1]

  1. Stalmans, P; Benz, MS; Gandorfer, A; Kampik, A; Girach, A; Pakola, S; Haller, JA; MIVI-TRUST Study, Group (2012 Aug 16). “Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.”. The New England journal of medicine 367 (7): 606–15.PMID 22894573.
Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: